Potential interactions between traditional Chinese medicine and osimertinib: a Case Report
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. A 57-year-old female was diagnosed...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1596913/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850108732920299520 |
|---|---|
| author | Min Zhang Huiwen Ma Wanyi Chen Zhongzhen Yuan |
| author_facet | Min Zhang Huiwen Ma Wanyi Chen Zhongzhen Yuan |
| author_sort | Min Zhang |
| collection | DOAJ |
| description | Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. A 57-year-old female was diagnosed with stage IV lung adenocarcinoma, who switched from gefitinib to osimertinib after disease progression. However, the carcinoembryonic antigen (CEA) results suggested biochemical recurrence after 48 months. The first osimertinib trough concentration (Ctrough) was 82.1 ng/mL, significantly lower than the FDA-reported 166 ng/mL, with concurrent elevation of the tumor marker carcinoembryonic antigen (CEA). After excluding other possible factors, the decreased osimertinib concentration might be due to the TCM taken by the patient. After adjusting the TCM prescription, the patient’s osimertinib Ctrough was stable within the range of 145 and 228 ng/mL without significant adverse reactions and carcinoembryonic antigen levels stabilized. This case underscored the importance of monitoring drug concentrations in patients concurrently using TCM and osimertinib to optimize treatment outcomes and minimize potential drug-drug interactions. |
| format | Article |
| id | doaj-art-47acb39df8d74e01b3b22647a2028e49 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-47acb39df8d74e01b3b22647a2028e492025-08-20T02:38:18ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.15969131596913Potential interactions between traditional Chinese medicine and osimertinib: a Case ReportMin Zhang0Huiwen Ma1Wanyi Chen2Zhongzhen Yuan3Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, ChinaDepartment of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, ChinaDepartment of Pharmacy, Chongqing University Cancer Hospital, Chongqing, ChinaDepartment of Pharmacy, Chongqing University Cancer Hospital, Chongqing, ChinaOsimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. A 57-year-old female was diagnosed with stage IV lung adenocarcinoma, who switched from gefitinib to osimertinib after disease progression. However, the carcinoembryonic antigen (CEA) results suggested biochemical recurrence after 48 months. The first osimertinib trough concentration (Ctrough) was 82.1 ng/mL, significantly lower than the FDA-reported 166 ng/mL, with concurrent elevation of the tumor marker carcinoembryonic antigen (CEA). After excluding other possible factors, the decreased osimertinib concentration might be due to the TCM taken by the patient. After adjusting the TCM prescription, the patient’s osimertinib Ctrough was stable within the range of 145 and 228 ng/mL without significant adverse reactions and carcinoembryonic antigen levels stabilized. This case underscored the importance of monitoring drug concentrations in patients concurrently using TCM and osimertinib to optimize treatment outcomes and minimize potential drug-drug interactions.https://www.frontiersin.org/articles/10.3389/fphar.2025.1596913/fullosimertinibtraditional Chinese medicine (TCM)drug-drug interactionnon-small cell lung cancertherapeutic drug monitoring |
| spellingShingle | Min Zhang Huiwen Ma Wanyi Chen Zhongzhen Yuan Potential interactions between traditional Chinese medicine and osimertinib: a Case Report Frontiers in Pharmacology osimertinib traditional Chinese medicine (TCM) drug-drug interaction non-small cell lung cancer therapeutic drug monitoring |
| title | Potential interactions between traditional Chinese medicine and osimertinib: a Case Report |
| title_full | Potential interactions between traditional Chinese medicine and osimertinib: a Case Report |
| title_fullStr | Potential interactions between traditional Chinese medicine and osimertinib: a Case Report |
| title_full_unstemmed | Potential interactions between traditional Chinese medicine and osimertinib: a Case Report |
| title_short | Potential interactions between traditional Chinese medicine and osimertinib: a Case Report |
| title_sort | potential interactions between traditional chinese medicine and osimertinib a case report |
| topic | osimertinib traditional Chinese medicine (TCM) drug-drug interaction non-small cell lung cancer therapeutic drug monitoring |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1596913/full |
| work_keys_str_mv | AT minzhang potentialinteractionsbetweentraditionalchinesemedicineandosimertinibacasereport AT huiwenma potentialinteractionsbetweentraditionalchinesemedicineandosimertinibacasereport AT wanyichen potentialinteractionsbetweentraditionalchinesemedicineandosimertinibacasereport AT zhongzhenyuan potentialinteractionsbetweentraditionalchinesemedicineandosimertinibacasereport |